Summary:
Veracyte’s Decipher Prostate Genomic Classifier data is now included in a new SEER Program database, enabling researchers to study its real-world impact on prostate cancer outcomes.
Three brief takeaways:
- The SEER database includes de-identified data from over 560,000 prostate cancer cases linked with Decipher test results.
- This collaboration enhances research opportunities and supports personalized treatment strategies based on genomic risk.
- Decipher is the only prostate cancer genomic test with “Level I” evidence and NCCN Guideline inclusion.
Veracyte, Inc., a cancer diagnostics company, has announced that data from its market-leading Decipher Prostate Genomic Classifier are available in a new specialized database that the National Cancer Institute’s (NCI’s) Surveillance, Epidemiology, and End Results (SEER) Program just released. This database will enable eligible researchers to evaluate Decipher Prostate test results in the context of real-world patient outcomes, prostate cancer characteristics, treatment protocols, demographics and other factors.
“We are excited about the numerous opportunities that our collaboration with the NCI SEER Program will enable for prostate cancer researchers and, ultimately, for patients,” says Philip Febbo, MD, Veracyte’s chief scientific officer and chief medical officer. “It also reinforces Veracyte’s commitment to building clinical evidence for our tests and to advancing scientific understanding of cancer and its biological underpinnings.”
NCI SEER Program Is an Authoritative Source of Cancer Data
The NCI SEER Program is an authoritative source of population-based information on cancer incidence and survival in the United States. The SEER specialized database containing de-identified Decipher Prostate Genomic Classifier data is based on a linkage conducted by the SEER registries and included over 560,000 prostate cancer cases diagnosed from 2010 to 2018. The Decipher Prostate test has been available for use on radical prostatectomy specimens since 2013 and on biopsy tissue since 2016.
About the Decipher Prostate Genomic Classifer
The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients with prostate cancer. The test is performed on biopsy or surgically resected samples and provides an accurate risk of developing metastasis with standard treatment. Armed with this information, physicians can better personalize their patients’ care and may recommend less-intensive options for those at lower risk or earlier, more-intensive treatment for those at higher risk of metastasis.
The Decipher Prostate test’s performance and clinical utility has been demonstrated in over 85 studies involving more than 200,000 patients. It is the only gene expression test to achieve “Level I” evidence status and inclusion in the risk-stratification table in the most recent NCCN Guidelines* for prostate cancer, according to the company.
Featured Image: One Photo | Dreamstime.com
* National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
